The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study
Rheumatology and therapy(2022)
Key words
Biosimilar,Adalimumab,Anti-TNF,Inflammatory rheumatic joint diseases,Disease activity,Nocebo effects
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined